Now Masimo is suing US Customs over Apple Watch imports

Medical tech firm Masimo is suing US Customs and Border Protection (CBP) after the agency permitted Apple to restore the blood oxygen tracking feature on Apple Watches, allegedly circumventing a December 2023 ITC import ban tied to Masimo's patent infringement. Masimo claims CBP created an unlawful loophole and failed to notify them of the decision reversal, asserting this action undermines its competitive standing and deviates from established regulatory practice. The lawsuit seeks to reinstate the original import restrictions, underscoring the ongoing intellectual property disputes and challenges in regulatory enforcement within the medical device and consumer electronics industries.

Analysis

Masimo (MASI) has escalated its intellectual property dispute by filing a lawsuit against US Customs and Border Protection (CBP), not just its primary competitor, Apple (AAPL). The core of the complaint is that the CBP created a procedural loophole that nullifies a December 2023 International Trade Commission (ITC) import ban, allowing Apple to re-enable the blood oxygen feature on its watches. Masimo alleges this decision was made without its notification, deviating from established practice and causing "irreparable" harm to its market standing. The negative sentiment score of -0.7 for MASI reflects the significant headwind of renewed, costly litigation against both a government agency and a corporate giant. For Apple, the CBP's ruling represents a major operational victory, mitigating the impact of the ITC ban on a key product feature, which is mirrored in its positive sentiment score of 0.6. This development introduces significant uncertainty around the enforcement power of ITC rulings and raises questions about whether large corporations can leverage technical workarounds or political influence, as alluded to by Masimo's reference to Apple's "substantial investments in the United States," to bypass patent restrictions.

Key Decisions for Investors

• Investors in Masimo (MASI) should view this lawsuit as a significant near-term headwind, and closely monitor court proceedings for the requested temporary restraining order, as its outcome will be a critical catalyst for the stock.
• For Apple (AAPL) investors, the CBP's decision is a bullish development that removes an overhang on Apple Watch sales, though the pending litigation from Masimo introduces renewed headline risk that could potentially reverse this favorable ruling.
• This case underscores the high-stakes legal and regulatory risks in the technology and medical device sectors, highlighting the challenge smaller patent-holders face in enforcing ITC rulings against well-capitalized corporations.